CRISPR Therapeutics

CRISPR Therapeutics presented progress on commercialization of CASGEVY and a broadening development pipeline at the Morgan Stanley Global Healthcare Conference. Vertex reported about $76 million in quarterly revenue for CASGEVY and more than 100 new treatments per quarter; management sees potential for annualized revenue well above $500 million and long-term up to $1 billion. Key programs with data expected by the end of 2026 include CTX310 (cardiovascular risk), CTX611 (Factor XI anticoagulation) and Zugo-cel (allogeneic CAR‑T for autoimmune diseases); additional early programs are slated to deliver initial data in early 2027. The company emphasizes sufficient funding to self-finance the pipeline, the use of AI to accelerate R&D, and a long-term strategy toward in vivo editing and gene insertion. » More on de.investing.com

A single IV infusion of CTX310 at the highest dose produced after one year a median reduction in ANGPTL3 of 79%, triglycerides of 48% and LDL of 53% versus baseline; maximum reductions were 89% (ANGPTL3), 78% (triglycerides) and 84% (LDL). The phase‑1a dose‑escalation study with 15 participants showed no dose‑limiting toxicities or serious treatment‑related adverse events; three grade‑2 infusion reactions resolved and a transient liver value increase was observed. CRISPR is continuing CTX310 in a phase‑1b fixed‑dose 0.8 mg/kg study and expects an update in the second half of 2026, focusing on patients with severe hypertriglyceridemia. » More on de.investing.com

CRISPR Therapeutics has seen modest stock gains this year but reported Q2 revenue rising to $10.2 million, narrower losses and a stronger cash position of $2.36 billion. Its commercial therapy Casgevy is driving revenue and received FDA approval for children aged 2 and up, potentially expanding the addressable market, while pipeline programs including CTX611 and off-the-shelf CAR-T candidates CTX112/CTX131 progress toward later-stage trials. Cathie Wood's Ark Invest holds 94.6 million shares at an average cost of $66, leaving the fund below breakeven at current prices, but the company says its improving finances could fund multiple upcoming clinical readouts. » More on finance.yahoo.com